Akorn Receives Second Warning Letter In Six Months

After receiving multiple Form 483s, Akorn receives yet another warning letter in the span of six months from the US Food and Drug Administration. 

Warning
Akorn has received an FDA warning letter for its facility in Somerset, New Jersey • Source: Shutterstock

Akorn has received its second warning letter from the US Food and Drug Administration in the span of six months. This warning letter was regarding the inspection that took place from 23 July to 30 August 2018 at Akorn’s Somerset, New Jersey facility.

An Akorn spokesperson told Generics Bulletin that the company “takes the FDA warning letter seriously and is working diligently to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business